Novel pedigree analysis implicates DNA repair and chromatin remodeling in multiple myeloma risk

PLoS Genetics

Volumn 14, Issue 2, 2018, Pages

  Waller, Rosalie G ^a   Darlington, Todd M ^a   Wei, Xiaomu ^b   Madsen, Michael J ^a   Thomas, Alun ^a   Curtin, Karen ^a   Coon, Hilary ^a   Rajamanickam, Venkatesh ^a   Musinsky, Justin ^c   Jayabalan, David ^b   Atanackovic, Djordje ^a   Rajkumar, S Vincent ^d   Kumar, Shaji ^d   Slager, Susan ^d   Middha, Mridu ^e   Galia, Perrine ^f   Demangel, Delphine ^f   Salama, Mohamed ^a   Joseph, Vijai ^c   McKay, James ^g   Offit, Kenneth ^c   Klein, Robert J ^e   Lipkin, Steven M ^b   Dumontet, Charles ^h   Vachon, Celine M ^d   Camp, Nicola J ^a   more..

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^d MAYO CLINIC   (United States)

^e MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^f ProfileXpert   (France)

^g INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

^h CENTRE DE RECHERCHE EN CANCÉROLOGIE DE LYON   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ENDONUCLEASE; GLUTAMIC ACID; GLUTAMINE; METHIONINE; SERINE;

ARTICLE; CANCER RISK; CHROMATIN ASSEMBLY AND DISASSEMBLY; CLINICAL ARTICLE; CONTROLLED STUDY; DNA REPAIR; ENZYME REGULATION; EXOME; GENE; GENE DELETION; GENE MAPPING; GENE SEQUENCE; GENETIC CODE; GENETIC HETEROGENEITY; GENETIC VARIATION; HUMAN; MONOCLONAL IMMUNOGLOBULINEMIA; MULTIPLE MYELOMA; PEDIGREE ANALYSIS; RISK ASSESSMENT; SINGLE NUCLEOTIDE POLYMORPHISM; USP45 GENE; CASE CONTROL STUDY; DNA MUTATIONAL ANALYSIS; DRUG EFFECT; FAMILY; FEMALE; GENETIC DATABASE; GENETIC PREDISPOSITION; GENETICS; GENOME-WIDE ASSOCIATION STUDY; MALE; PEDIGREE;

CASE-CONTROL STUDIES; CHROMATIN ASSEMBLY AND DISASSEMBLY; DATABASES, GENETIC; DNA MUTATIONAL ANALYSIS; DNA REPAIR; FAMILY; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENETIC VARIATION; GENOME-WIDE ASSOCIATION STUDY; HUMANS; MALE; MULTIPLE MYELOMA; PEDIGREE;

EID: 85043303673     PISSN: 15537390     EISSN: 15537404     Source Type: Journal    
DOI: 10.1371/journal.pgen.1007111     Document Type: Article

References (62)

1. Maher B, Personal genomes: The case of the missing heritability. Nature. 2008;456: 18–21. doi: 10.1038/456018a 18987709
2. Manolio TA, Collins FS, Cox NJ, Goldstein DB, Hindorff LA, Hunter DJ, et al. Finding the missing heritability of complex diseases. Nature. 2009;461: 747–53. doi: 10.1038/nature08494 19812666
3. Eichler EE, Flint J, Gibson G, Kong A, Leal SM, Moore JH, et al. Missing heritability and strategies for finding the underlying causes of complex disease. Nat Rev Genet. 2010;11: 446–50. doi: 10.1038/nrg2809 20479774
4. Miki Y, Swensen J, Shattuck-Eidens D, Futreal PA, Harshman K, Tavtigian S, et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science. 1994;266: 66–71. Available: http://www.ncbi.nlm.nih.gov/pubmed/7545954 7545954
5. Wooster R, Neuhausen SL, Mangion J, Quirk Y, Ford D, Collins N, et al. Localization of a breast cancer susceptibility gene, BRCA2, to chromosome 13q12-13. Science. 1994;265: 2088–90. Available: http://www.ncbi.nlm.nih.gov/pubmed/8091231 8091231
6. Vance JM, Pericak-Vance MA, Yamaoka LH, Speer MC, Rosenwasser GO, Small K, et al. Genetic linkage mapping of chromosome 17 markers and neurofibromatosis type I. Am J Hum Genet. 1989;44: 25–9. Available: http://www.ncbi.nlm.nih.gov/pubmed/2491777 2491777
7. Cannon-Albright LA, Goldgar DE, Meyer LJ, Lewis CM, Anderson DE, Fountain JW, et al. Assignment of a locus for familial melanoma, MLM, to chromosome 9p13-p22. Science. 1992;258: 1148–52. Available: http://www.ncbi.nlm.nih.gov/pubmed/1439824 1439824
8. Leppert M, Dobbs M, Scambler P, O’Connell P, Nakamura Y, Stauffer D, et al. The gene for familial polyposis coli maps to the long arm of chromosome 5. Science. 1987;238: 1411–3. Available: http://www.ncbi.nlm.nih.gov/pubmed/3479843 3479843
9. Nishisho I, Nakamura Y, Miyoshi Y, Miki Y, Ando H, Horii A, et al. Mutations of chromosome 5q21 genes in FAP and colorectal cancer patients. Science. 1991;253: 665–9. Available: http://www.ncbi.nlm.nih.gov/pubmed/1651563 1651563
10. Ng SB, Buckingham KJ, Lee C, Bigham AW, Tabor HK, Dent KM, et al. Exome sequencing identifies the cause of a mendelian disorder. Nat Genet. 2010;42: 30–5. doi: 10.1038/ng.499 19915526
11. Ng SB, Bigham AW, Buckingham KJ, Hannibal MC, McMillin MJ, Gildersleeve HI, et al. Exome sequencing identifies MLL2 mutations as a cause of Kabuki syndrome. Nat Genet. 2010;42: 790–3. doi: 10.1038/ng.646 20711175
12. McClellan J, King M-C, Genetic Heterogeneity in Human Disease. Cell. 2010;141: 210–217. doi: 10.1016/j.cell.2010.03.032 20403315
13. Mitchell KJ, What is complex about complex disorders?Genome Biol. 2012;13: 237. doi: 10.1186/gb-2012-13-1-237 22269335
14. Li X, Montgomery SB, Detection and Impact of Rare Regulatory Variants in Human Disease. Front Genet. 2013;4. doi: 10.3389/fgene.2013.00067 23755067
15. Albert FW, Kruglyak L, The role of regulatory variation in complex traits and disease. Nat Rev Genet. 2015;16: 197–212. doi: 10.1038/nrg3891 25707927
16. Knight S, Abo RP, Abel HJ, Neklason DW, Tuohy TM, Burt RW, et al. Shared Genomic Segment Analysis: The Power to Find Rare Disease Variants. Ann Hum Genet. 2012;76: 500–509. doi: 10.1111/j.1469-1809.2012.00728.x 22989048
17. Myeloma—SEER Stat Fact Sheets [Internet]. Available: https://seer.cancer.gov/statfacts/html/mulmy.html
18. Cannon-Albright LA, Thomas A, Goldgar DE, Familiality of cancer in Utah. Cancer Res. 1994;54: 2378–2385. 8162584
19. Landgren O, Linet MS, McMaster ML, Gridley G, Hemminki K, Goldin LR, Familial characteristics of autoimmune and hematologic disorders in 8,406 multiple myeloma patients: A population-based case-control study. Int J Cancer. 2006;118: 3095–3098. doi: 10.1002/ijc.21745 16395700
20. Albright F, Teerlink C, Werner TL, Cannon-Albright LA, Significant evidence for a heritable contribution to cancer predisposition: a review of cancer familiality by site. BMC Cancer. BioMed Central Ltd; 2012;12: 138. doi: 10.1186/1471-2407-12-138 22471249
21. Schinasi LH, Brown EE, Camp NJ, Wang SS, Hofmann JN, Chiu BC, et al. Multiple myeloma and family history of lymphohaematopoietic cancers: Results from the International Multiple Myeloma Consortium. Br J Haematol. England; 2016;175: 87–101. doi: 10.1111/bjh.14199 27330041
22. Landgren O, Kristinsson SY, Goldin LR, Caporaso NE, Blimark C, Mellqvist U-H, et al. Risk of plasma cell and lymphoproliferative disorders among 14621 first-degree relatives of 4458 patients with monoclonal gammopathy of undetermined significance in Sweden. Blood. 2009;114: 791–5. doi: 10.1182/blood-2008-12-191676 19182202
23. Greenberg AJ, Rajkumar SV, Vachon CM, Familial monoclonal gammopathy of undetermined significance and multiple myeloma: epidemiology, risk factors, and biological characteristics. Blood. 2012;119: 5359–66. doi: 10.1182/blood-2011-11-387324 22354002
24. Greenberg AJ, Rajkumar SV, Larson DR, Dispenzieri A, Therneau TM, Colby CL, et al. Increased prevalence of light chain monoclonal gammopathy of undetermined significance (LC-MGUS) in first-degree relatives of individuals with multiple myeloma. Br J Haematol. 2012;157: 472–5. Available: http://www.ncbi.nlm.nih.gov/pubmed/22629552 22629552
25. Vachon CM, Kyle RA, Therneau TM, Foreman BJ, Larson DR, Colby CL, et al. Increased risk of monoclonal gammopathy in first-degree relatives of patients with multiple myeloma or monoclonal gammopathy of undetermined significance. Blood. 2009;114: 785–90. doi: 10.1182/blood-2008-12-192575 19179466
26. Thomas A, Camp NJ, Farnham JM, Allen-Brady K, Cannon-Albright LA, Shared Genomic Segment Analysis. Mapping Disease Predisposition Genes in Extended Pedigrees Using SNP Genotype Assays. Ann Hum Genet. 2008;72: 279–287. 10.1111/j.1469-1809.2007.00406.x doi: 10.1111/j.1469-1809.2007.00406.x 18093282
27. Lander E, Kruglyak L, Genetic dissection of complex traits: guidelines for interpreting and reporting linkage results. Nat Genet. 1995;11: 141–147.
28. Lek M, Karczewski KJ, Minikel E V, et al. Analysis of protein-coding genetic variation in 60,706 humans. Nature. Nature Research; 2016;536: 285–291. doi: 10.1038/nature19057 27535533
29. Myeloma data downloaded from the dbGaP web site under accessions: phs000348.v2.p1 and phs000748.v4.p3. [Internet].
30. Control data downloaded from the dbGaP web site under accessions: phs000209.v13.p3, phs000276.v2.p1, phs000179.v5.p2, phs000298.v3.p2, phs000424.v6.p1, phs000653.v2.p1, phs000687.v1.p1, phs000814.v1.p1, and phs000806.v1.p1.
31. Perez-Oliva AB, Lachaud C, Szyniarowski P, Muñoz I, Macartney T, Hickson I, et al. USP45 deubiquitylase controls ERCC1-XPF endonuclease-mediated DNA damage responses. EMBO J. 2015;34: 326–43. doi: 10.15252/embj.201489184 25538220
32. USP45 in the GG-NER Incision Complex [Internet]. Available: http://www.reactome.org/PathwayBrowser/#/R-HSA-5696398&SEL=R-HSA-5696465&PATH=R-HSA-73894
33. Marteijn JA, Lans H, Vermeulen W, Hoeijmakers JHJ, Understanding nucleotide excision repair and its roles in cancer and ageing. Nat Rev Mol Cell Biol. 2014;15: 465–81. doi: 10.1038/nrm3822 24954209
34. Kirschner K, Melton DW, Multiple roles of the ERCC1-XPF endonuclease in DNA repair and resistance to anticancer drugs. Anticancer Res. 2010;30: 3223–3232. 30/9/3223 [pii] 20944091
35. Friedberg EC, How nucleotide excision repair protects against cancer. Nat Rev Cancer. 2001;1: 22–33. doi: 10.1038/35094000 11900249
36. Christmann M, Tomicic MT, Roos WP, Kaina B, Mechanisms of human DNA repair: an update. Toxicology. 2003;193: 3–34. Available: http://www.ncbi.nlm.nih.gov/pubmed/14599765 14599765
37. SWI/SNF Chromatin Remodeling Complex [Internet]. Available: http://www.reactome.org/PathwayBrowser/#/R-HSA-5696398&PATH=R-HSA-73894
38. Biegel JA, Busse TM, Weissman BE, SWI/SNF chromatin remodeling complexes and cancer. Am J Med Genet C Semin Med Genet. 2014;166C: 350–66. doi: 10.1002/ajmg.c.31410 25169151
39. Romero O a, Sanchez-Cespedes M,.The SWI/SNF genetic blockade: effects in cell differentiation, cancer and developmental diseases. Oncogene. Nature Publishing Group; 2014;33: 2681–9. doi: 10.1038/onc.2013.227 23752187
40. Roberts CWM, Orkin SH, The SWI/SNF complex—chromatin and cancer. Nat Rev Cancer. Nature Publishing Group; 2004;4: 133–142. Available: http://dx.doi.org/10.1038/nrc1273 14964309
41. Lek M, Karczewski KJ, Minikel E V., Samocha KE, Banks E, Fennell T, et al. Analysis of protein-coding genetic variation in 60,706 humans. Nature. Nature Research; 2016; 536: 285–291. doi: 10.1038/nature19057 27535533
42. Cai Z, Camp NJ, Cannon-Albright L, Thomas A, Identification of regions of positive selection using Shared Genomic Segment analysis. Eur J Hum Genet. Nature Publishing Group; 2011;19: 667–671. doi: 10.1038/ejhg.2010.257 21304558
43. Morgan GJ, Johnson DC, Weinhold N, Goldschmidt H, Landgren O, Lynch HT, et al. Inherited genetic susceptibility to multiple myeloma. Leukemia. 2014;28: 518–24. doi: 10.1038/leu.2013.344 24247655
44. Broderick P, Chubb D, Johnson DC, Weinhold N, Försti A, Lloyd A, et al. Common variation at 3p22.1 and 7p15.3 influences multiple myeloma risk. Nat Genet. Nature Publishing Group; 2011;44: 58–61. doi: 10.1038/ng.993.Common 22120009
45. Chubb D, Weinhold N, Broderick P, Chen B, Johnson DC, Försti A, et al. Common variation at 3q26.2, 6p21.33, 17p11.2 and 22q13.1 influences multiple myeloma risk. Nat Genet. Nature Publishing Group; 2013;45: 1221–1225. doi: 10.1038/ng.2733 23955597
46. Weinhold N, Johnson DC, Chubb D, Chen B, Försti A, Hosking FJ, et al. The CCND1 c.870G>A polymorphism is a risk factor for t(11;14)(q13;q32) multiple myeloma. Nat Genet. 2013;45: 522–5. doi: 10.1038/ng.2583 23502783
47. Swaminathan B, Thorleifsson G, Jöud M, Ali M, Johnsson E, Ajore R, et al. Variants in ELL2 influencing immunoglobulin levels associate with multiple myeloma. Nat Commun. 2015;6: 7213. doi: 10.1038/ncomms8213 26007630
48. Mitchell JS, Li N, Weinhold N, Försti A, Ali M, Duin M Van, et al. Genome-wide association study identifies multiple susceptibility loci for multiple myeloma. Nat Commun. 2016;7: 12050. doi: 10.1038/ncomms12050 27363682
49. Nie Z, Xue Y, Yang D, Zhou S, Deroo BJ, Archer TK, et al. A specificity and targeting subunit of a human SWI/SNF family-related chromatin-remodeling complex. Mol Cell Biol. 2000;20: 8879–88. Available: http://www.ncbi.nlm.nih.gov/pubmed/11073988 11073988
50. Jones S, Wang T-L, Shih I-M, Mao T-L, Nakayama K, Roden R, et al. Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma. Science. 2010;330: 228–31. doi: 10.1126/science.1196333 20826764
51. Hodges C, Kirkland JG, Crabtree GR, The Many Roles of BAF (mSWI/SNF) and PBAF Complexes in Cancer. Cold Spring Harb Perspect Med. 2016;6. doi: 10.1101/cshperspect.a026930 27413115
52. Puente XS, Beà S, Valdés-Mas R, Villamor N, Gutiérrez-Abril J, Martín-Subero JI, et al. Non-coding recurrent mutations in chronic lymphocytic leukaemia. Nature. 2015;526: 519–524. doi: 10.1038/nature14666 26200345
53. Lunning MA, Green MR, Mutation of chromatin modifiers; an emerging hallmark of germinal center B-cell lymphomas. Blood Cancer J. 2015;5: e361. doi: 10.1038/bcj.2015.89 26473533
54. Choi J, Goh G, Walradt T, Hong BS, Bunick CG, Chen K, et al. Genomic landscape of cutaneous T cell lymphoma. Nat Genet. 2015;47: 1–11. doi: 10.1038/ng.3188
55. Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MAR, Bender D, et al. PLINK: A Tool Set for Whole-Genome Association and Population-Based Linkage Analyses. Am J Hum Genet. 2007;81: 559–575. doi: 10.1086/519795 17701901
56. 1000 Genomes Project ConsortiumAuton A, Brooks LD, Durbin RM, Garrison EP, Kang HM, et al. A global reference for human genetic variation. Nature. 2015;526: 68–74. doi: 10.1038/nature15393 26432245
57. Abel HJ, Thomas A, Accuracy and Computational Efficiency of a Graphical Modeling Approach to Linkage Disequilibrium Estimation. Stat Appl Genet Mol Biol. 2011;10. doi: 10.2202/1544-6115.1615 21291415
58. Matise TC, Chen F, Chen W, De La Vega FM, Hansen M, He C, et al. A second-generation combined linkage physical map of the human genome. Genome Res. 2007;17: 1783–6. doi: 10.1101/gr.7156307 17989245
59. Lauritzen SL, Graphical models. Clarendon Press; 1996.
60. Linderman MD, Brandt T, Edelmann L, Jabado O, Kasai Y, Kornreich R, et al. Analytical validation of whole exome and whole genome sequencing for clinical applications. BMC Med Genomics. 2014;7: 20. doi: 10.1186/1755-8794-7-20 24758382
61. Paila U, Chapman BA, Kirchner R, Quinlan AR, Gardner PP, GEMINI: Integrative Exploration of Genetic Variation and Genome Annotations. PLoS Comput Biol. 2013;9: e1003153. doi: 10.1371/journal.pcbi.1003153 23874191
62. Neale BM, Rivas MA, Voight BF, Altshuler D, Devlin B, Orho-Melander M, et al. Testing for an unusual distribution of rare variants. PLoS Genet. 2011;7. doi: 10.1371/journal.pgen.1001322 21408211